TITLE

Tengion closes $33 million Series C financing round

PUB. DATE
October 2007
SOURCE
Medical Device Daily;10/18/2007, Vol. 11 Issue 200, p5
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports that Tengion has closed a $33 million Series C financing, including participation from new investor Deerfield Partners. The company will use the proceeds from this financing to advance the late-stage clinical development of its Tengion Neo-Bladder Augment and to accelerate expansion of its regenerative medicine platform into the development of other autologous organs and tissues in the genitourinary and cardiovascular systems.
ACCESSION #
27165957

 

Related Articles

  • bluebird bio Secures $60 Mln in Oversubscribed Financing.  // Biomedical Market Newsletter;7/26/2012, Vol. 21, p1 

    The article informs that bluebird bio LLC has completed a 60 million Series D financing. It also informs that in the process, new investors including Deerfield Partners, RA Capital and two undisclosed blue chip public investment funds have joined existing investors including ARCH Venture...

  • Financings Roundup.  // BioWorld Today;5/4/2011, Vol. 22 Issue 86, p3 

    The article reports on the plan of Boulder, Colorado-based Array BioPharma Inc. to issue 30 million U.S. dollars of its Series B Preferred Stock to those affiliated with Deerfield Partners.

  • Financings Roundup.  // BioWorld Today;10/ 4/2012, Vol. 23 Issue 193, p5 

    The article reports on the pricing made by Tengion Inc. for a 15 million-dollar in senior secured convertible notes for a private placement with some of its investors.

  • Bluebird Soaring with $60M Series D for Gene Therapy. Boggs, Jennifer // BioWorld Today;7/25/2012, Vol. 23 Issue 143, p1 

    The article reports on the 60 million dollar Series D financing closed by bluebird bio. Nick Leschly, chief executive officer (CEO) of the company, describes the transaction as an opportunistic financing for bluebird which is preparing to begin a trial for a lead program in rare disease...

  • Array BioPharma Announces $30 Mln Debt Reduction and a Loan Term Extension to 2015 and 2016.  // Biomedical Market Newsletter;5/5/2011, p420 

    The article reports on the agreements signed by Array BioPharma Inc. with Deerfield Partners for the modification of its credit facility and the issuance of its $30 million Series B Preferred Stock to entities associated with the latter company. It points out that the sale of the Preferred...

  • Investors to the Rescue as Tengion Pulls in $31M PIPE.  // Bioworld Week;3/7/2011, Vol. 19 Issue 10, p4 

    The article reports on Tengion Inc, as it is backed by Minneapolis, Minnesota-based medical device company Medtronic Inc., on Tengion's financing needs in a PIPE transaction involving the exchange of 11.1 million shares of common stocks.

  • Medtronic, investors to put $31.4 million into Tengion.  // Medical Device Daily;3/2/2011, Vol. 15 Issue 41, p1 

    This article reports on the participation of Medtronic in a financing for fellow medical device company Tengion in 2011.

  • Stock Movers.  // BioWorld Today;2/9/2011, Vol. 22 Issue 27, p2 

    A list of biotechnology companies with significant stock changes as of February 8, 2011 is presented including Tengion Inc. and EpiCept Corp.

  • Financings Roundup.  // BioWorld Today;9/12/2012, Vol. 23 Issue 177, p2 

    This section offers news briefs on financing deals including a plan by Sequenom Inc. to issue convertible senior notes due 2017 via a private offering and the one-month bridge loan arranged by Tengion Inc. with leading investors.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics